Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction

Journal of Urology

Volumn 158, Issue 4, 1997, Pages 1403-1407

  Cawello, Willi ^a   Schweer, Horst ^a   Dietrich, Bruno ^a   Seyberth, Hannsjorg Wilhelm ^a   Albrecht, Detlef ^a   Fox, Alanna ^a   Hohmuth, Horst ^a  

^a NONE

Author keywords

Infusions, intravenous; Penis; Pharmacokinetics; Prostaglandins E

Indexed keywords

13,14 DIHYDRO 15 OXOPROSTAGLANDIN E2; 13,14 DIHYDROPROSTAGLANDIN E1; DRUG METABOLITE; PROSTAGLANDIN E1;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; GAS CHROMATOGRAPHY; HEADACHE; HEART RATE; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030750961     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64226-5     Document Type: Article

References (17)

1. Ishii, N., Watanabe, H., Irisawa, C., Kikuchi, Y., Kawamura, S., Suzuki, K., Chiba, R., Tokiwa, M. and Shirai, M.: Studies on male sexual impotence. Report 18. Therapeutic trial with prostaglandin E1 for organic impotence. Nippon Hinyokika Gakkai Zasshi, 77: 954, 1986.
2. Stackl, W., Hasun, R. and Marberger, M.: Intracavernous injection of prostaglandin E1 in impotent men. J. Urol., 140: 66, 1988.
3. Porst, H., van Ahlen, H., Block, T., Halbig, W., Hautmann, R., Löchner-Ernst, D., Rudnick, J., Staehler, G., Weber, H. M., Weidner, W. and Weiske, W. H.: Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction. VASA, suppl., 28: 50, 1989.
4. Schramek, P. and Waldhauser, M.: Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction. Brit. J. Clin. Pharmacol., 28: 567, 1989.
5. Gerber, G. S. and Levine, L. A.: Pharmacological erection program using prostaglandin E1. J. Urol., 146: 786, 1991.
6. Roy, A. C., Adaikan, P. G., Sen, D. K. and Ratnam, S. S.: Prostaglandin-15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection. Brit. J. Urol., 64: 180, 1989.
7. van Ahlen, H., Peskar, B. A., Sticht, G. and Hertfelder, H.-J.: Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J. Urol., 151: 1227, 1994.
8. Cawello, W., Schweer, H., Müller, R., Bonn, R. and Seyberth, H. W.: Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects. Eur. J. Clin. Pharmacol., 46: 275, 1994.
9. Bähren, W. and Stief, C. G.: Intracavernous Pharmaco Testing. Impotence-Diagnostic and Therapy. Edited by W. Bähren and J. E. Altwein. Stuttgart: Georg Thieme Verlag, 1989.
10. Schweer, H., Meese, C. O., Watzer, B. and Seyberth, H. W.: Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry. Biol. Mass. Spectr., 23: 165, 1994.
11. Cawello, W., Leonhardt, A., Schweer, H., Seyberth, H. W., Bonn, R. and Lomeli, A. L.: Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. Brit. J. Clin. Pharmacol., 40: 273, 1995.
12. Fournier, G. R., Jr., Juenemann, K.-P., Lue, T. F. and Tanagho, E. A.: Mechanism of venous occlusion during canine penile erection: an anatomic demonstration. J. Urol., 137: 163, 1987.
13. Kattan, S., Collins, J. P. and Mohr, D.: Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence. Urology, 37: 516, 1991.
14. Tanaka, T.: Papaverine hydrochloride in peripheral blood and the degree of penile erection. J. Urol., 143: 1135, 1990.
15. Costa, P., Bressolle, F., Sarrazin, B., Mosser, J., Navratil, H. and Galtier, M.: Moxisylyte plasma kinetics in humans after intracavernous administration. Biopharmaceut. Drug Dispos., 13: 671, 1992.
16. Hakenberg, O., Wetterauer, U., Koppermann, U. and Lühmann, R.: Systemic pharmacokinetics of papaverine and phentolamine: comparison of intravenous and intracavernous application. Int. J. Impot. Res., suppl. 2, 2: 247, 1990.
17. Porst, H.: The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J. Urol., 155: 802, 1996.